These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer. Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427 [No Abstract] [Full Text] [Related]
13. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Dhillon S. Drugs; 2010 Mar 05; 70(4):489-512. PubMed ID: 20205490 [Abstract] [Full Text] [Related]
16. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes. Gallwitz B. Drugs Today (Barc); 2007 Oct 05; 43(10):681-9. PubMed ID: 17987221 [Abstract] [Full Text] [Related]
18. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Curr Med Res Opin; 2008 Feb 05; 24(2):489-96. PubMed ID: 18182122 [Abstract] [Full Text] [Related]
19. Sitagliptin and metformin--novel combination therapy. Seyoum B. Expert Opin Pharmacother; 2011 Mar 05; 12(4):641-6. PubMed ID: 21291346 [Abstract] [Full Text] [Related]